Smith-Lemli-Opitz syndrome (SLOS) is a malformation disorder caused by mutations in DHCR7, which impair the reduction of 7-dehydrocholesterol (7DHC) to cholesterol. SLOS results in cognitive impairment, behavioral abnormalities and nervous system defects, though neither affected cell types nor impaired signaling pathways are fully understood. Whether 7DHC accumulation or cholesterol loss is primarily responsible for disease pathogenesis is also unclear. Using induced pluripotent stem cells (iPSCs) from subjects with SLOS, we identified cellular defects that lead to precocious neuronal specification within SLOS derived neural progenitors. We also demonstrated that 7DHC accumulation, not cholesterol deficiency, is critical for SLOS-associated defects. We further identified downregulation of Wnt/b-catenin signaling as a key initiator of aberrant SLOS iPSC differentiation through the direct inhibitory effects of 7DHC on the formation of an active Wnt receptor complex. Activation of canonical Wnt signaling prevented the neural phenotypes observed in SLOS iPSCs, suggesting that Wnt signaling may be a promising therapeutic target for SLOS. npg
Impaired cholesterol synthesis underlies a group of human disorders characterized by cognitive impairment, congenital malformations, and distinct behavioral phenotypes, including autism 1 . The most common cholesterol synthesis disorder, Smith-Lemli-Opitz syndrome (SLOS), results from mutations in the 3β-hydroxysterol-∆ 7 -reductase gene (DHCR7). Impaired DHCR7 activity inhibits the reduction of 7-dehydrocholesterol (7DHC) to cholesterol, resulting in lower cholesterol and higher 7DHC levels 2 . Cholesterol participates in multiple biological functions in the context of neurodevelopment and normal neuronal function, including synaptic activity, signal transduction, and myelination, and it acts as a precursor for neuroactive steroids [3] [4] [5] [6] . Whereas the cholesterol synthesis defect in SLOS may underlie pathological changes in multiple tissues, neurocognitive manifestations remain a major clinical issue. However, the precise effects of altering sterol composition on central nervous system (CNS) malformations, as well as on the cognitive and behavioral deficits found in SLOS patients, are unknown 7, 8 . Furthermore, it is unclear whether the SLOS phenotype is a result of cholesterol deficiency or the effects of 7DHC accumulation 9, 10 . Thus, although the SLOS biochemical defect is well defined, neither the specific mechanisms nor the role of decreased cholesterol versus increased 7DHC in SLOS CNS pathogenesis have been clearly delineated 1 .
RESULTS

Development of an iPSC model of SLOS
To gain insight into the mechanisms underlying neural phenotypes of SLOS, we generated iPSCs via lentiviral transduction with the loxPflanked STEMCCA polycistronic vector 11 . Fibroblasts from five subjects with SLOS were selected to obtain iPSCs representative of the SLOS phenotypic spectrum ( Supplementary Table 1 ). We generated and analyzed ≥2 lines corresponding to each SLOS subject to limit heterogeneity 12 . No major differences in reprogramming efficiency were found between control and SLOS samples.
When cultured in cholesterol-replete medium, both SLOS and control iPSCs exhibited typical human embryonic stem cell (hESC) morphology and high expression of pluripotent surface markers and core transcription factors relative to hESCs ( Fig. 1a-c,  Supplementary Fig. 1a-c and Supplementary Table 2 ). All iPSCs used in this study were karyotypically normal over >30 passages, demonstrated silencing of viral reprogramming factors, and maintained patient-specific DHCR7 mutations ( Supplementary  Fig. 1d-f) . To confirm the differentiation capacity of iPSCs, we performed in vitro and in vivo germ layer differentiation assays. Analysis of differentiated iPSCs at the transcriptional, protein, and histological levels demonstrated that SLOS and control iPSCs contribute to all three germ layers ( Fig. 1d, Supplementary Fig. 2 and Supplementary Video 1).
To induce cholesterol synthesis and cause 7DHC accumulation in SLOS cell lines, iPSCs were transferred from cholesterol-replete hESC medium to cholesterol-deficient mTeSR1 medium 13 . We confirmed that mTeSR1 medium was cholesterol deficient by gas chromatography-mass spectroscopy analysis (GC/MS) (0.33 ± 0.15 µg cholesterol/ml in mTeSR1 versus 9.83 ± 0.40 µg cholesterol/ml in 20% KOSR hESC medium). As expected, hESCs and control iPSCs did not accumulate either 7DHC or 8-dehydrocholesterol (8DHC; an isomer of 7DHC), and they maintained normal cholesterol levels in both cholesterol-replete and cholesterol-deficient medium. In contrast, SLOS iPSCs cultured in cholesterol-deficient mTeSR1 medium demonstrated lower cholesterol levels and higher 7DHC and 8DHC levels compared to hESC and iPSC controls ( Fig. 1e-h) . These experiments validate the pluripotent capacity of SLOS iPSCs and confirm retention of the expected biochemical defect.
DHCR7 mutations result in stem cell defects and aberrant neural differentiation
We have previously identified increased dendritic and axonal growth in hippocampal neurons derived from Dhcr7 −/− mice 14 and characterized structural abnormalities, including cerebral and cerebellar atrophy, in the CNS of SLOS subjects 7 , suggesting that DHCR7 mutations may affect neural development. The generation of neural rosettes, representing early neural progenitors of the developing CNS, is a standard assay for neural progenitor derivation 15 . To analyze SLOS iPSC neural progenitors, we generated neurospheres in cholesterolreplete medium and plated them onto laminin-coated dishes in cholesterol-deficient neural induction medium. Although hESCs and control iPSCs demonstrated robust formation of rosettes positive for the transcription factors SOX2 and PAX6 ( Fig. 2a) , SLOS iPSCgenerated SOX2-and PAX6-positive rosette structures were poorly defined and displayed accelerated neuronal differentiation, as evidenced by higher expression of the neuronal marker βIII-tubulin compared to ESC and iPSC controls ( Fig. 2a and Supplementary  Fig. 3a,b ). qRT-PCR analysis showed lower PAX6 expression and concomitantly higher MAP2 (encoding microtubule-associated protein 2) and SOX10 expression in SLOS iPSCs compared to controls, suggesting neuronal and neural crest specification, respectively ( Fig. 2b) . However, expression of ALDH1L1, a glia-specific marker, was similar in all cultures ( Fig. 2b) . Extended differentiation assays revealed lower PAX6 expression in SLOS iPSCs relative to controls, along with continued expansion of βIII-tubulin networks ( Supplementary Fig. 3c-e ), formation of long neuronal projections ( Supplementary Fig. 3f ), and higher expression of the neuronal transcripts TUBB3, MAP2, and SYP (Supplementary Fig. 3g-i) .
Owing to the neural progenitor defects and augmented neuronal differentiation observed in SLOS iPSCs, we wanted to determine whether SLOS iPSC pluripotency was affected in cultures grown in cholesterol-deficient medium. Control and SLOS iPSCs were shifted to feeder-independent cultures in cholesterol-deficient mTeSR1 medium for expansion in pluripotent conditions 13 . Control iPSCs maintained pluripotent morphology in mTeSR1; however, SLOS iPSCs exhibited a spindled, neural progenitor-like phenotype (Fig. 2c) . Structural analysis of SLOS iPSCs cultured in mTeSR1 revealed fewer cell-to-cell contacts as compared with hESCs, as well as the generation of secondary filaments, which are indicators characteristic of the loss of pluripotency, as compared with hESCs ( Fig. 2d) . To determine whether cholesterol supplementation would prevent the loss of SLOS iPSC pluripotency, mTeSR1-cultured SLOS iPSCs were supplemented with 10 µg cholesterol/ml of medium with either high-density lipoprotein (HDL) or low-density lipoprotein (LDL). Immunocytochemical analysis revealed higher expression of the pluripotency marker TRA-1-81 + in LDL-supplemented SLOS iPSCs, as compared to untreated or HDL-supplemented cultures ( Fig. 2e,f) . We confirmed that this effect was not specific to mTeSR1, as we found that SLOS iPSCs cultured in XF-KSR medium, another feeder-independent, cholesteroldeficient medium (1.85 ± 0.18 µg cholesterol/ml), also exhibited precocious differentiation, as evidenced by low expression of TRA-1-81 + (Fig. 2f) . LDL supplementation also maintained SLOS iPSC gap and tight junctions and prevented secondary filament formation ( Fig. 2d) . Cholesterol supplementation also allowed for the formation of morphologically normal SLOS rosette structures which were comparable to those in control iPSCs ( Fig. 2g) . SLOS rosettes could be isolated and expanded as neural progenitor lines when cultured with continuous cholesterol supplementation. Expandable SLOS progenitors maintained robust SOX2 and human nestin (hNestin) expression without formation of βIII-tubulin + neurons ( Fig. 2h) .
To identify differentiation networks resulting from impaired endogenous cholesterol synthesis, we analyzed SLOS iPSCs for protein and transcriptional changes 7 d after initiating cholesterol-deficient culture. SLOS iPSCs exhibited the loss of the pluripotency marker NANOG and the emergence of PAX6 + and hNestin + neural progenitors within differentiating cultures ( Fig. 3a,c,d) . qPCR confirmed lower expression of POU5F1 (pluripotency marker) and higher expression of PAX6 (CNS progenitor marker) and SNAI2 (marker of the neural crest and epithelial-to-mesenchymal transition) in SLOS iPSC lines ( Fig. 3b) . However, little change was observed in VIM (mesodermal and mesenchymal marker) or AFP (endodermal marker) expression. Of note, the degree of aberrant differentiation and neural fate choice seemed to correlate with phenotypic severity. SLOS iPSCs from moderately affected subjects (CW and CWI) and a severely affected subject (A2) showed a loss of pluripotency markers such as POU5F1 and higher expression of the neural crest marker SNAI2. However, relative to A2-derived lines, the iPSCs derived from moderately affected subjects demonstrated lower expression of CNS progenitor markers ( Fig. 3b,d) .
Aberrant SLOS differentiation is caused by 7DHC accumulation
To determine whether aberrant neuronal differentiation in SLOS was due to low cholesterol or elevated 7DHC, hESCs were treated with inhibitors of cholesterol-synthetic enzymes other than DHCR7, causing cholesterol loss without DHC accumulation. Treatment of hESCs with simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, induced sterol regulatory element binding transcription factor 2 (SREBP2)-dependent gene expression, thereby confirming the functional inhibition of endogenous cholesterol synthesis (Supplementary Fig. 3a ). Although treatment with simvastatin inhibited cellular proliferation, hESC morphology was maintained and no change in pluripotency-or lineage-specific transcript expression was observed ( Supplementary Fig. 3b,c) . Treatment of hESCs with U18666A to both inhibit desmosterol reductase (DHCR24) and induce endolysosomal accumulation of unesterified cholesterol 16 reduced cholesterol content and induced desmosterol accumulation. However, we observed no change in hESC morphology or pluripotency-and tissue-specific gene expression ( Supplementary  Fig. 4a,b,d) . In contrast, treatment of hESCs with the DHCR7 inhibitor AY9944 (ref. 17 ) caused marked accumulation of 7DHC and induced aberrant neural differentiation similar to that observed in SLOS iPSCs (Supplementary Fig. 4a-c) . AY9944 treatment also inhibited rosette npg formation and induced βIII-tubulin expression in control iPSC neural differentiation assays ( Supplementary Fig. 5a,b) .
To further address the specificity of defects in cholesterol homeostasis on aberrant differentiation observed in SLOS iPSCs, we generated iPSCs from subjects with either Niemann-Pick disease, type C1 (NPC1) or lathosterolosis. In NPC1, intracellular cholesterol transport is impaired, resulting in endolysosomal accumulation of unesterified cholesterol and decreased intracellular cholesterol bioavailability 18 . Of note, elevated DHC levels in SLOS cells can induce an NPC-like accumulation of unesterified cholesterol 19 . Whereas NPC1 iPSCs demonstrated increased filipin staining of unesterified cholesterol in cholesterol-replete conditions, they maintained a pluripotent morphology when cultured in either cholesterol-replete or cholesteroldeficient conditions (Supplementary Fig. 6a ). Further, qRT-PCR analysis confirmed that no major changes occurred in the expression of neural crest or epithelial-to-mesenchymal transition (SNAI2), neuroectoderm (PAX6), or pluripotency (NANOG, POU5F1) markers ( Supplementary Fig. 6b ). Lathosterolosis, an inborn error of cholesterol synthesis due to mutation of the lathosterol 5-desaturase (SC5D) gene, impairs the conversion of lathosterol to 7DHC 20 npg than 7DHC. Lathosterolosis iPSCs exhibited lathosterol accumulation, pluripotent transcript expression, and pluripotent protein expression comparable to hESCs, while maintaining pluripotent morphology when cultured in either cholesterol-replete or cholesterol-deficient conditions ( Supplementary Fig. 7a-f ).
7DHC directly inhibits Wnt/b-catenin activity
To identify signaling pathways that mediate aberrant neural formation in SLOS iPSCs, we performed a time-course, whole-genome analysis of cDNA transcripts in control iPSCs versus SLOS iPSCs ( Fig. 3e) . We compared transcript expression between cell lines npg and within cell lines over time to determine how control iPSCs and SLOS iPSCs respond to cholesterol deficient conditions. Comparative analyses revealed that SLOS iPSCs cultured in cholesterol-deficient conditions initiated transcriptional networks that led to epithelial-to-mesenchymal transition and initiation of neural differentiation, as well as to loss of cadherin-associated signaling, kinase signaling, pluripotency and Wnt signaling ( Supplementary Tables 3 and 4) . By examining the earliest time points at the initiation of differentiation, we observed 44 genes that were differentially expressed between control and SLOS iPSCs. Within this differentially expressed gene cluster, a number are associated with Wnt/β-catenin signaling (including CAV1, CDH1, and SNAI2) ( Fig. 3f,g) , suggesting a probable role for Wnt/β-catenin signaling in SLOS iPSC neural specification.
Wnt signaling inhibits formation of the Axin/APC/GSK3β scaffolding complex and allows β-catenin accumulation 21, 22 , regulation of neurogenesis 23 , cortical differentiation 24 and hESC neural differentiation 25 . The PDZ domain of dishevelled (DVL) binds cholesterol, which is an essential interaction for the scaffolding function of DVL 26 .
To determine whether 7DHC might disrupt the cholesterol-dependent scaffolding function of DVL, we measured the binding of the DVL2-PDZ domain to plasma membrane (PM)-mimetic vesicles containing cholesterol or 7DHC, respectively, by surface plasmon resonance (SPR) analysis ( Fig. 4a,b) . The DVL2-PDZ domain exhibited 20-fold lower affinity for 7DHC-containing vesicles than for cholesterol-containing vesicles (Fig. 4b) . To test whether 7DHC accumulation reduces the PM binding and scaffolding activity of DVL2 under physiological conditions, we monitored the dynamic colocalization of DVL2 and Frizzled-7 (FZ7) in HeLa cells by simultaneous single-molecule tracking that allows sensitive and quantitative detection of dynamic and transient interactions among signaling proteins 26, 27 . Activation of the FZ7 receptor by WNT3A dramatically enhanced the dynamic colocalization of Halo-tag tetramethylrhodamine (TMR)-labeled FZ7 and EGFP-tagged DVL2 on the PM (Fig. 4c,d) . Substitution of cholesterol in the PM with 7DHC by treating cells with the methyl-β-cyclodextrin (MβCD)-7DHC complex greatly decreased the WNT3A-induced dynamic colocalization of DVL2 and FZ7 (Fig. 4c,d) . In contrast, treatment of cells with the same ratio of the MβCD-cholesterol complex had little effect on the interaction of DVL2 and FZ7 (Fig. 4c,d) . Similarly, WNT3A enhanced the dynamic colocalization of FZ7 and LRP6, which was abrogated by treatment with MβCD-7DHC but not MβCD-cholesterol (Fig. 4e) . These results support the notion that 7DHC accumulation inhibits 
Stabilization of b-catenin activity prevents aberrant SLOS iPSC differentiation
We next investigated whether altered Wnt/β-catenin signaling could underlie the aberrant SLOS iPSC neural differentiation. Treatment of SLOS iPSCs in cholesterol-deficient conditions with the GSK3β inhibitor CHIR99021 prevented loss of pluripotent morphology, whereas controls exhibited mild differentiation, suggesting that optimal cellular levels of β-catenin are essential for pluripotency maintenance (Fig. 5a) . Either recombinant Wnt3A or CHIR99021 treatment stabilized the expression of active β-catenin comparable to that of cholesterol-replete conditions and maintained total β-catenin expression similar to that of hESCs ( Fig. 5b) . To determine whether β-catenin maintenance prevented SLOS iPSC differentiation, we quantitified colonies for TRA-1-60 expression. CHIR99021 treatment, without cholesterol supplementation, prevented a loss of pluripotency comparable to that of LDL cholesterol treatment (Fig. 5c) .
To examine the consequences of β-catenin stabilization in SLOS iPSCs, we analyzed the effect of CHIR99021 on proteins associated with Wnt signaling, cell-to-cell contact, and pluripotency. CHIR99021 induced expression of the phosphorylated active form of the Wnt signaling co-receptor LRP6, as well as active β-catenin, OCT4 and E-cadherin (Fig. 5d,e and Supplementary Fig. 8) . The effects of CHIR99021 were more robust than LDL supplementation, suggesting that the loss of Wnt/β-catenin activity probably initiates SLOS iPSC neural differentiation. Further, the molecular response of iPSCs derived from severe (A2)-versus moderate (CWI)-phenotype subjects suggests the degree of DHCR7 inhibition may discriminately affect Wnt/β-catenin signaling events, thereby supporting the phenotypedependent differentiation we observed. DHCR7 effects on Wnt signaling were not restricted to iPSCs, as additional analyses demonstrated reduced β-catenin activity in SLOS iPSC rosette assays (Fig. 5g) , AY9944-treated control iPSC rosette assays, and the cerebral cortex of Dhcr7 −/− mice ( Fig. 5f and Supplementary Fig. 8e,f) . However, we did not observe altered β-catenin activity in lathosterolosis iPSCs, which maintained pluripotency and β-catenin activity in both cholesterolreplete and cholesterol-deficient conditions (Fig. 5h) .
To determine whether the aberrant differentiation of SLOS iPSCs has an in vivo correlate, we examined proliferation and cortical layer formation within Dhcr7 −/− mice. Quantification of Nissl staining and Ki67 + proliferating cells revealed layering defects within the subventricular and intermediate zones of the embryonic day 18,5 (E18.5) cortex (Supplementary Fig. 9a-c) and a loss of Ki67 expression within outer cortical layers (Supplementary Fig. 9d-f ).
Isogenic control for effects of DHCR7 on b-catenin activity
To confirm the effects of DHCR7 on Wnt/β-catenin signaling in a pluripotent isogenic cell line, we targeted the exon 8-intron 9 boundary of the DHCR7 locus with clustered regularly interspersed short palindromic repeats (CRISPR)-Cas9 nucleases in hESCs (Fig. 6a) . After nucleofection and antibiotic selection of transfected clones, a hESC clone (designated H1:DHCR7 Mut ) was found to contain a single nucleotide insertion at the 5′ position of exon 9 (c.1237_38insG), which altered the reading frame of DHCR7 and c -Wnt3a npg eliminated the stop codon at c.1699_1701 (Fig. 6a) . We observed no insertion or deletion events at ten predicted off-target sites that we assayed by Sanger sequencing (Supplementary Fig. 10) . This clone maintained a normal karyotype and expression of pluripotency markers over multiple passages in cholesterol-replete conditions. To determine whether this insertion event would induce SLOS-like biochemical defects, we cultured H1:DHCR7 Mut iPSCs in cholesterol-deficient mTeSR1 medium and analyzed them by GC/MS. H1:DHCR7 Mut cells recapitulated the SLOS biochemical defect ( Fig. 6b) . qRT-PCR analysis of H1:DHCR7 Mut cells maintained in cholesterol-deficient conditions confirmed patterns of differentiation similar to those of SLOS iPSCs, including significant upregulation of PAX6 and SNAI2 (Fig. 6c) . Finally, although H1:DHCR7 Mut iPSCs maintained pluripotent morphology and high β-catenin activity in cholesterol-replete medium, cholesterol-deficient culture in mTeSR1 induced differentiation to a neural progenitor-like phenotype, increased expression of hNestin, and attenuation of β-catenin activity (Fig. 6d) 
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DISCUSSION
We have used iPSC neural derivatives to identify a previously unrecognized cellular defect associated with SLOS. Our data strongly support a model in which 7DHC disruption of DVL scaffolding function leads to dysregulated Wnt/β-catenin activity (Fig. 6e) . Dysregulated Wnt/β-catenin activity, in turn, results in precocious neural differentiation of SLOS iPSCs and suggests that progenitor defects may contribute to the SLOS neural phenotype. Within the CNS, altered Wnt/β-catenin has distinct effects on fate choice in radial glia and intermediate cortical progenitors, suggesting that these effects may be cell type or niche dependent 24, 28 . β-catenin regulates neural progenitors within the cerebral cortex and affects excitatory neuronal formation [28] [29] [30] . Loss of neural progenitor maintenance is consistent with the microcephalic phenotype observed in individuals with SLOS 1 . Wnt signaling defects may contribute to the functional and developmental defects found in Dhcr7 −/− mouse excitatory neurons 14 and the neurodevelopmental malformations and dysfunction observed in subjects with SLOS 1 . Future work in inborn errors of cholesterol synthesis will need to discern the specific effects of cholesterol synthesis mechanisms on β-catenin-dependent (canonical) versus β-catenin-independent (non-canonical) Wnt signaling in neural phenotypes 31 . Furthermore, recently identified defects in Wnt/β-catenin signaling associated with autistic-like symptoms 32, 33 suggests the potential for broader implications of sterol and Wnt-signaling interactions. It is also unclear how cholesterol and Wnt interactions may affect disease pathogenesis through progenitor defects or differentiation in non-neural tissues 34, 35 . The use of SLOS iPSCs will enable further exploration of these effects. Our work using multiple iPSC models of cholesterol synthesis disorders and small molecules reveals substantial differences in cell fate choices between these diseases in response to cholesterol-deficient conditions, thus highlighting the complex and varied phenotypes underlying cholesterol synthesis disorders. Our findings also highlight the utility of iPSCs for modeling rare diseases and identifying previously unrecognized signaling mechanisms that underlie disease pathology. These studies provide a necessary framework for the comparison of the neurodevelopmental pathology in disorders of cholesterol synthesis with that of other neurological syndromes.
METHODS
Methods and any associated references are available in the online version of the paper. 
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ONLINE METHODS
Reagents and cell culture. hESCs and human iPSCs were maintained on inactivated mouse embryonic fibroblasts (MEFs; Global Stem) in hESC medium: DMEM/F12 base, 2 mM l-glutamine, 20% Knockout Serum Replacement, 1% non-essential amino acids (NEAA), 1,000 units/ml Penicillin-streptomycin, 100 µM β-mercaptoethanol (Life Technologies), and basic fibroblast growth factor (bFGF; 7.5 ng/ml; Stemgent). Feeder-free cultures were maintained in mTeSR1 (Stem Cell Technologies) on hESC-qualified Matrigel (BD Biosciences) coated culture dishes or chamber slides. Colonies were routinely passaged with dispase (1 mg/ml; Stem Cell Technologies) or manual dissection. Cultures were routinely analyzed by PCR for mycoplasma contamination/DNA (Universal Mycoplasma Detection Kit; ATCC). To begin cholesterol deficient pluripotent culture, colonies were either passaged by manual dissection or dispase treatment, rinsed with DMEM/F12, and transferred in mTeSR1 to Matrigel coated dishes. Dispase passage of cells growing in mTeSR1 used ROCK inhibitor supplementation (Y27632; 10 µM; Reagents Direct) for 24 h. Though the complete formulation of mTeSR1 designates it as maintaining low cholesterol content (1.12E-03 mM; 0.433 µg cholesterol/mL), mTeSR1 was batch tested for maintenance of hESC pluripotent morphology and analyzed by GC/MS for µg cholesterol/ml medium. Small molecules and recombinant proteins used in this study include: Wnt3A (100 ng/ml; R&D systems), CHIR99021 (3 µM; Reagents Direct), AY9944 (2.5 µM) and U18666A (100 nM; Sigma-Aldrich). High-density lipoprotein (HDL; density 1.063-1.21 g/ml) and low-density lipoprotein (LDL; density 1.019-1.063 g/ml) were isolated from human plasma by sequential ultracentrifugation and dialysis, as previously published 36 . Research strictly adhered to federal regulations and NIH policies regarding the responsible use of human pluripotent stem cells. Human ESC lines WA01 and WA09 have been approved for federal use and can be found on the NIH Human Embryonic Stem Cell Registry (#0043 and #0062). Lentiviral reprogramming of subject fibroblasts. Skin punch biopsies were collected from SLOS and lathosterolosis subjects according to NIH policies under IRB protocol number 98-CH-0081, 02-CH-0311 and 06-CH-0186. BJ human neonatal fibroblasts (cat. no. CRL-2522; ATCC) and human lung fibroblasts (cat. no. GM05387; Coriell Institute) were used to generate control iPSC lines designated BJ and HDF, respectively. Control iPSC lines SCU i19 and SCU i21 were a kind gift from Barbara Mallon and the NIH Stem Cell Unit. Fibroblasts were expanded and reprogrammed to pluripotency via lentiviral transduction with three-factor (OCT4, SOX2, KLF4) or four-factor (OCT4, SOX2, KLF4, c-MYC) STEMCCA reprogramming plasmid (kind gift from Dr. Gustavo Mostoslavksy, Boston University) using published methods 11 . After viral transduction, fibroblasts were passaged to MEF-coated 100-mm dishes and cultured for an additional 21-42 d. Individual clones were manually isolated and transferred to MEF-coated six-well dishes for expansion. Transgene excision was performed by FuGene HD (Roche) transfection of iPSCs with Cre-IRES-PuroR (gift from Darrell Kotton; Addgene; plasmid 30205) 11 , followed by puromycin (Sigma) selection.
Immunocytochemistry. Cells plated to chamber slides were fixed in 4% PFA for 15 min at room temperature, washed with PBS, and permeabilized with 0.2% Triton X-100 (Sigma) in PBS (PBS-T) for 20 min. To limit non-specific binding, cells were incubated for 1 h in 5% normal donkey or goat serum (Cell Signaling) diluted in PBS-T (blocking buffer). Cells were incubated overnight in blocking buffer containing the following primary antibodies: rabbit anti-Nanog (1:400; Cell Signaling; D73G4), rabbit anti-Oct4A (1:400; Cell Signaling; C30A3), mouse anti-SSEA4 (1:400; Cell Signaling; MC813), mouse anti-Tra-1-60 (1:400; Cell Signaling; TRA-1-60), mouse anti-Tra-1-81 (1:400; Cell Signaling; TRA-1-81), rabbit anti-Sox2 (1:400; Cell Signaling; D6D9), rabbit anti-E-cadherin (1:1,000; Cell Signaling; 24E10), mouse anti-Pax6 (1:2,000; Developmental Studies Hybridoma Bank; PAX6), mouse anti-βIII-tubulin (1:2,000; Millipore; MAB1637), mouse anti-active β-catenin (1:1,000; Millipore; 05-665), mouse anti-human nestin (1:2,000; Millipore; MAB5326), goat anti-Nkx2.5 (1:200; Santa Cruz Biotechnologies; SC-14033), and goat anti-GATA4 (1:200; Santa Cruz Biotechnologies; SC-1237). Cells were rinsed and primary antibodies detected with 555 donkey anti-rabbit IgG (1:500; Life Technologies; A-31572), 555 donkey anti-mouse IgG (1:500; Life Technologies; A-31570), 488 goat anti-rabbit IgG (A-11008), 488 goat anti-mouse IgG (1:500; Life Technologies; A-11001), or 555 donkey anti-goat (1:500; Life Technologies; A-21432). Nuclei were counterstained with Hoechst 33342 (Life Technologies). Slides were mounted with ProLong Gold Antifade (Life Technologies) before imaging with a Leica DMI4000B or Leica DM6000B microscope. Images were processed with Volocity (PerkinElmer) and Adobe Photoshop (Adobe Systems) software. TRA-1-60 and TRA-1-81 positivity was quantified on the basis of >50% of the colony area exhibiting both pluripotent morphology and positive staining.
Real-time qRT-PCR. Samples were collected via centrifugation and RNA isolated using the PicoPure Isolation kit (Life Technologies) with DNase I (Qiagen) per manufacturer instructions. cDNA was generated from 1 µg of RNA via the SuperScript III First-Strand Synthesis kit (Life Technologies). Real-time qPCR was performed using custom-designed primers and SYBR Green I Master mix (Roche) on a Lightcycler 480. Expression levels were normalized to GAPDH expression. Primer sequences used to detect endogenous expression of KLF4 and SOX2 were previously published 37 . Custom designed primer sequences used are available upon request.
Teratoma formation and analysis. Teratoma assays were performed by Applied Stem Cell (Menlo Park, CA). Control and patient iPSCs in hESC medium on a MEF feeder layer were harvested by 1 mg/ml dispase, collected by centrifugation, and resuspended in 30% Matrigel. iPSCs (1.5 × 10 6 ) were injected under the kidney capsule and testis of three nonobese diabetic (NOD)/severe-combined immunodeficient (SCID) mice for BJ 3F-1 control iPSC and A2 3F-2 SLOS iPSC lines. Tumors developed within 4-8 weeks, at which time they were isolated after mouse euthanasia and formalin fixation. After sectioning, teratomas were analyzed for germ layer formation on the basis of H&E staining.
Analysis of patient-specific mutations in DHCR7 and SC5D. DNA was isolated using the DNeasy kit (Qiagen), confirmed for quality by Nanodrop spectrophotometry analysis, and analyzed for patient-specific mutations using previously published primer sequences and PCR conditions 2, 20, 38 . For Sanger sequencing, 100 ng of DNA was used for each PCR reaction using primers spanning DHCR7 regions with known mutations. 1-5 µl of PCR reaction was purified with Exosap-IT (Fisher Scientific). 4 µl of Exosap reaction product was mixed with BigDye Terminator Mix (Applied Biosystems), buffer and primers, followed by the following reaction conditions: 96 °C for 10 s, 50 °C for 10 s, 60 °C for 4 min. This cycle was repeated 30 times followed by Sephadex G50 (Sigma-Aldrich) purification of PCR fragments. Sequencing was performed on a 3130x1 Sequencer (Applied Biosystems) and chromatograms exported using SnapGene.
GS/MS spectrometry in hESCs and iPSCs.
Cell pellets flash frozen on dry ice received 1 ml water and were lysed by freeze/thaw method in a 55 °C water bath. 100 µl per sample was removed and analyzed for protein concentration by Bradford assay (Bio-Rad). 1 ml buffer containing 92% C 2 H 6 O, 7% KOH, and 1% coprostan-3-ol (Sigma) was added per sample, shaken, and saponified at 60 °C for 1 h. 1 ml water was then added per sample, followed by organic extraction with 3 ml ethyl acetate. Samples were vortexed, centrifuged, and the organic phase removed. Samples were then dried by heating at 60 °C concurrent with nitrogen gas flow for lipid isolation. Extracted lipids were derivatized with 50 µl pyridine CHROMASOLV Plus (Sigma) and 50 µl N,O-bis(trimethylsilyl) trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) (Pierce Biotechnology) per sample, followed by 1 h of incubation at 60 °C. Samples were then transferred to amber tubes and sterol levels were measured on an Ultra Trace GC (Thermo Scientific). Analysis was performed with XCalibur software (Thermo Scientific). Peak identification for specific sterols was based on known sterol retention time, retention time of coprostanol as an internal standard (~14 min), and comparison to the National Institute of Standards and Technologies Standard Reference data set. For peak quantification, the area
